Insights

Gathering insights about SPARC…

Similar companies to SPARC

SPARC Tech Stack

SPARC uses 8 technology products and services including RSS, MySQL, Google Fonts API, and more. Explore SPARC's tech stack below.

RSS
Content Management System
MySQL
Database
Google Fonts API
Font Scripts
Typed.js
Javascript Libraries
imagesLoaded
Javascript Libraries
OWL Carousel
Javascript Libraries
UPS
Logistics
Facebook
Widgets

Media & News

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
NeuroThera's Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the United States Patent and Trademark Office has granted a U.S. patent for NeuroThera's proprietary combination of antimicrobials and cannabinoids.
Feb 02, 2026 | www.globenewswire.com
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials February 2, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), today announced that the United States Patent and Trademark Office has granted a U.S. patent for its proprietary combination of antimicrobials and cannabinoids. This patent covers innovative compositions and methods of potentiating antimicrobials, specifically designed to enhance the efficacy of existing antibiotics against resistant bacterial strains.
Feb 02, 2026 | www.thenewswire.com
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd.
Jan 26, 2026 | www.globenewswire.com
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing
Jan 13, 2026 | www.globenewswire.com
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the “Notification Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated November 18, 2025, the Company reported stockholders' equity of approximately $(81,000) as of June 30, 2025.
Jan 12, 2026 | www.globenewswire.com
Neurothera Labs Announces Results of AGM
January 8, 2026 – TheNewswire - Vancouver, British Columbia, Canada – Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce the results of its annual and special meeting of shareholders (“ AGM ”) held today. All of the nominee directors listed in Neurothera's management information circular dated December 4, 2025 (the “ Circular ”) were elected as directors. Furthermore, shareholders of the Company voted in favour of appointing Dale Matheson Carr-Hilton Labonte LLP as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration.
Jan 08, 2026 | www.thenewswire.com
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues.
Dec 30, 2025 | www.globenewswire.com

SPARC's Email Address Formats

SPARC uses at least 2 format(s):

SPARC Email Formats	Example	Percentage
First@livermoreshakes.org	John@livermoreshakes.org	80%
First.Last@livermoreshakes.org	John.Doe@livermoreshakes.org	20%
First@sparctheater.org	John@sparctheater.org	100%

Frequently Asked Questions

What is SPARC's stock symbol?

SPARC is a publicly traded company; the company's stock symbol is SPRC.

What is SPARC's official website and social media links?

SPARC's official website is sparctheater.org and has social profiles on LinkedIn.

What is SPARC's NAICS code?

SPARC's NAICS code is 7111 - Performing Arts Companies.

How many employees does SPARC have currently?

As of January 2026, SPARC has approximately 21 employees across 1 continents, including North America. Key team members include Managing Director: L. S.Stage Management Apprentice: E. L.. Explore SPARC's employee directory with LeadIQ.

What industry does SPARC belong to?

SPARC operates in the Performing Arts industry.

What technology does SPARC use?

SPARC's tech stack includes RSSMySQLGoogle Fonts APITyped.jsimagesLoadedOWL CarouselUPSFacebook.

What is SPARC's email format?

SPARC's email format typically follows the pattern of First@livermoreshakes.org. Find more SPARC email formats with LeadIQ.

When was SPARC founded?

SPARC was founded in 2006.

SPARC

Q: What is SPARC's official website and social media links?

SPARC's official website is sparctheater.org. SPARC has social profiles on LinkedIn.

Q: How many employees does SPARC have currently?

SPARC has approximately 21 employees.

Q: What technology does SPARC use?

SPARC's tech stack includes Font Awesome, MixItUp, core-js, oEmbed, Typed.js.

Performing ArtsCalifornia, United States11-50 Employees

Formerly known as Livermore Shakespeare Festival, we have been lighting a SPARC in the Tri-Valley for 20 years through high quality theatrical experiences in vineyards, public establishments, performing arts venues, schools, colleges and universities.

Company Overview

Website: sparctheater.org
Stock Symbol: SPRC
NAICS Code: 7111 - Performing Arts Companies
Founded: 2006
Employees: 11-50

Media & News

Funding & Financials

$1M
SPARC's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
SPARC's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to SPARC

Santa Cruz Shakespeare

Oregon Shakespeare Festival

San Francisco Shakespeare Festival

MARIN SHAKESPEARE COMPANY

Berkeley Repertory Theatre

California Shakespeare Theater

SPARC Tech Stack

Media & News

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Neurothera Labs Announces Results of AGM

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

SPARC's Email Address Formats

Frequently Asked Questions

What is SPARC's stock symbol?

What is SPARC's official website and social media links?

What is SPARC's NAICS code?

How many employees does SPARC have currently?

What industry does SPARC belong to?

What technology does SPARC use?

What is SPARC's email format?

When was SPARC founded?

SPARC

Company Overview

Media & News

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?